Glyn Hughes

Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin.

1 Capsazepine is a synthetic analogue of the sensory neurone excitotoxin, capsaicin. The present study shows the capsazepine acts as a competitive antagonist of capsaicin. 2 Capsazepine (10 μm) reversibly reduced or abolished the current response to capsaicin (500 nm) of voltage‐clamped dorsal root ganglion (DRG) neurones from rats. In contrast, the responses to 50 μm γ‐aminobutyric acid (GABA) and 5 μm adenosine 5′‐triphosphate (ATP) were unaffected. 3 The effects of capsazepine were examined quantitatively with radioactive ion flux experiments. Capsazepine inhibited the capsaicin (500 nm)‐induced 45Ca2+ uptake in cultures of rat DRG neurones with an IC50 of 420 ± 46 nm (mean ± s.e.mean, n = 6). The 45Ca2+ uptake evoked by resiniferatoxin (RTX), a potent capsaicin‐like agonist was also inhibited. (Log concentration)‐effect curves for RTX (0.3 nm‐1 μm) were shifted in a competitive manner by capsazepine. The Schild plot of the data had a slope of 1.08 ± 0.15 (s.e.) and gave an apparent Kd estimate for capsazepine of 220 nm (95% confidence limits, 57–400 nm). 4 Capsazepine also inhibited the capsaicin‐ and RTX‐evoked efflux of 86Rb+ from cultured DRG neurones. The inhibition appeared to be competitive and Schild plots yielded apparent Kd estimates of 148 nm (95% confidence limits, 30–332 nm) with capsaicin as the agonist and 107 nm (95% confidence limits, 49–162 nm) with RTX as agonist. 5 A similar competitive inhibition by capsazepine was seen for capsaicin‐induced [14C]‐guanidinium efflux from segments of adult rat vagus nerves (apparent Kd = 690 nm; 95% confidence limits, 63 nm‐1.45 μm). No significant difference was noted in the apparent Kd estimates for capsazepine in assays on cultured DRG neurones and vagus nerve as shown by the overlap in the 95% confidence limits. 6 Capsazepine, at concentrations up to 10 μm, had no significant effects on the efflux of 86Rb+ from cultured DRG neurones evoked either by depolarization with high (50 mm) K+ solutions or by acidification of the external medium to pH 5.0–5.6. Similarly capsazepine had no significant effect on the depolarization (50 mm KCl)‐induced efflux of [14C]‐guanidinium from vagus nerve preparations. 7 Ruthenium Red was also tested for antagonism against capsaicin evoked [14C]‐guanidinium release from vague nerves and capsaicin induced 45Ca2+ uptake in cultures of DRG neurones. In contrast to capsazepine the inhibition by Ruthenium Red (10–500 nm in DRG and 0.5–10 μm in vagus nerve experiments) was not consistent with a competitive antagonism, but rather suggested a more complex, non‐competitive inhibition.

Bradyzide, a potent non-peptide B2 bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia

Bradyzide is from a novel class of rodent‐selective non‐peptide B2 bradykinin antagonists (1‐(2‐Nitrophenyl)thiosemicarbazides). Bradyzide has high affinity for the rodent B2 receptor, displacing [3H]‐bradykinin binding in NG108‐15 cells and in Cos‐7 cells expressing the rat receptor with KI values of 0.51±0.18 nM (n=3) and 0.89±0.27 nM (n=3), respectively. Bradyzide is a competitive antagonist, inhibiting B2 receptor‐induced 45Ca efflux from NG108‐15 cells with a pKB of 8.0±0.16 (n=5) and a Schild slope of 1.05. In the rat spinal cord and tail preparation, bradyzide inhibits bradykinin‐induced ventral root depolarizations (IC50 value; 1.6±0.05 nM (n=3)). Bradyzide is much less potent at the human than at the rodent B2 receptor, displacing [3H]‐bradykinin binding in human fibroblasts and in Cos‐7 cells expressing the human B2 receptor with KI values of 393±90 nM (n=3) and 772±144 nM (n=3), respectively. Bradyzide inhibits bradykinin‐induced [3H]‐inositol trisphosphate (IP3) formation with IC50 values of 11.6±1.4 nM (n=3) at the rat and 2.4±0.3 μM (n=3) at the human receptor. Bradyzide does not interact with a range of other receptors, including human and rat B1 bradykinin receptors. Bradyzide is orally available and blocks bradykinin‐induced hypotension and plasma extravasation. Bradyzide shows long‐lasting oral activity in rodent models of inflammatory hyperalgesia, reversing Freunds complete adjuvant (FCA)‐induced mechanical hyperalgesia in the rat knee joint (ED50, 0.84 μmol kg−1; duration of action >4 h). It is equipotent with morphine and diclofenac, and 1000 times more potent than paracetamol, its maximal effect exceeding that of the non‐steroidal anti‐inflammatory drugs (NSAIDs). Bradyzide does not exhibit tolerance when administered over 6 days. In summary, bradyzide is a potent, orally active, antagonist of the B2 bradykinin receptor, with selectivity for the rodent over the human receptor.

Design of non-peptide CCK2 and NK1 peptidomimetics using 1-(2-nitrophenyl)thiosemicarbazide as a novel common scaffold

A beta-turn overlay hypothesis has been used to transform the core scaffold of a selective non-peptide bradykinin B2 receptor antagonist into ligands specifically recognized by the CCK2 or NK1 receptors.